The Current State of PSSD Recovery Research
PSSD recovery research is in its early stages. The EMA's 2019 recognition was a turning point that has spurred academic interest, but the field lacks the large-scale longitudinal studies needed to characterise recovery trajectories with confidence.
The most important published data on recovery comes from Studt et al. (2021), which followed a cohort of PSSD patients over time and documented outcomes:
| Outcome Category | Percentage of Patients | Notes |
|---|---|---|
| No improvement or worsening | 37% | Significant minority with persistent or worsening symptoms |
| Some improvement | ~40% | Partial recovery — symptoms reduced but not resolved |
| Significant improvement or recovery | ~23% | Substantial or complete resolution of symptoms |
| Median time to improvement (partial) | 1–3 years (community reports) | Highly variable; some recover faster, some slower |
Community-Reported Recovery Timelines
In the absence of large-scale clinical data, community surveys from PSSD forums provide the most comprehensive picture of recovery timelines. Key patterns from community data:
- Emotional symptoms (blunting, anhedonia) tend to improve before sexual symptoms in patients who do recover
- Genital numbness is reported as the most persistent symptom — consistent with the small-fiber neuropathy hypothesis (Heikkinen 2022) suggesting a structural component
- Recovery, when it occurs, is typically gradual rather than sudden
- Relapses are reported — some patients experience windows of improvement followed by worsening
- Stress and illness are commonly reported as triggers for symptom worsening
Clinical Trials in Progress
As of 2026, PSSD-specific clinical trials are limited but growing. The EMA's recognition has created a regulatory framework that makes PSSD a legitimate research target. Academic groups in Finland (following the Heikkinen 2022 biopsy study), the UK, and the United States are investigating PSSD mechanisms and potential interventions.
The growing body of psilocybin research has created indirect relevance to PSSD recovery research. Multiple psilocybin trials for depression, PTSD, and addiction are generating neuroplasticity data that is mechanistically relevant to PSSD — even though none of these trials specifically target PSSD.
The Neuroplasticity Framework for Recovery
The most promising conceptual framework for PSSD recovery is neuroplasticity — the brain's ability to restore receptor density, circuit function, and synaptic connectivity given the right conditions.
According to Shrooomz's research into serotonergic health, the neuroplasticity research most relevant to PSSD recovery includes:
- Raval et al. (2021) — Single psilocybin dose increased synaptic density in the prefrontal cortex by ~10% within 24 hours in rodents. This demonstrates that neuroplasticity-promoting interventions can rapidly restore synaptic architecture.
- Drewko et al. (2025) — Confirmed neuroplasticity-promoting effects of psilocybin in human subjects, providing translational evidence for the rodent findings.
- Exercise research — Aerobic exercise consistently upregulates BDNF and promotes neuroplasticity across multiple brain regions. This provides a low-risk, accessible approach to supporting the neuroplasticity processes relevant to PSSD recovery.
None of this research was conducted in PSSD patients. The neuroplasticity framework for PSSD recovery is mechanistically plausible but clinically unvalidated. It does, however, provide a rational basis for the approaches that PSSD patients report finding most helpful — and for cautious optimism about the trajectory of PSSD research.
Reasons for Cautious Optimism
Despite the challenging prognosis data from Studt et al. 2021, there are genuine reasons for optimism:
- 63% of patients in Studt et al. reported some degree of improvement — recovery is possible
- The EMA's 2019 recognition has legitimised PSSD as a research target and accelerated funding
- Growing mechanistic understanding (small-fiber neuropathy, 5-HT2A downregulation, epigenetic changes) enables more targeted research
- The neuroplasticity literature provides a conceptual framework for recovery interventions
- Patient advocacy communities have become sophisticated research partners, accelerating data collection and trial recruitment
Explore Shrooomz Botanical Supplements
USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.
View Our Supplements →Return to the PSSD Resource Hub. Related: Natural Approaches to PSSD | Can Psilocybin Help With PSSD? | Why Your Doctor Doesn't Know About PSSD | Emotional Numbness After Stopping Antidepressants | Psilocybin vs Antidepressants
Ready to experience the difference?
Shop Secret Shrooomz →Frequently Asked Questions
Is recovery from PSSD possible?
Yes, some patients do experience improvement, but outcomes vary and are not guaranteed. Data from Studt et al. (2021) indicate a mixed picture with a substantial minority not improving.
What did Studt et al. (2021) find about outcomes?
They followed a cohort of people with PSSD and found that about 63% reported some improvement while 37% had no improvement or worsening. The time course of recovery ranged from months to over a decade, underscoring substantial variability.
Are there any approved treatments for PSSD?
Currently, there are no approved treatments for PSSD. Management tends to be symptom-focused and individualized, with limited high-quality evidence supporting specific interventions.
How does psilocybin relate to PSSD in terms of treatment potential?
Psilocybin is explored for its potential to promote neuroplastic changes that could help affected neural circuits, offering a theoretical basis for recovery. However, direct evidence for PSSD is limited and conclusions must await rigorous clinical research.
How long can recovery take for PSSD?
Reported durations range from months to more than a decade. Some individuals experience improvements that stabilize, while others may see stable or persistent symptoms for extended periods.
How strong is the current evidence on PSSD recovery?
The evidence base is still small and early. Much of what is known comes from limited cohorts and retrospective reports, with a need for larger, longitudinal studies; EMA recognition in 2019 has spurred further research but conclusions remain tentative.